Hepatitis B Vaccines ; Humans ; Vaccination

In the past 5 years,the treatment paradigm for patients with follicular lymphoma(FL) has undergone significant changes,with the development of effective new agents that are now being used in the upfront,maintenance,and relapsed/refractory settings.Although these new therapies have led to improvements in patient outcomes,numerous questions remain regarding their optimal use in the treatment of the disease.In this article,the questions related to the timing of therapy for asymptomatic patients,strategies for treating advanced and relapsed/refractory disease,the safety and efficacy of rituximab maintenance and the evolving role of transplantation in the era of novel agents were responded.The latest data from clinical trials of investigational agents that are showing promise in FL were also discussed.

Intensive multidrug regimens,such as rituximah plus fractionated cyclophsphamide,vincristine,doxorubicin,and dexamethasone(R-HyperCVAD),are now being used to improve outcomes in patients with mantle cell lymphoma(MCL).In addition to these combinations,novel targeted agents,including bortezomib,bendamustine,and lenalidomide,are also being integrated into the treatment paradigm.Given the wide array of therapies available,making and implementing treatment decisions has become a complex process,requiring interdisciplinary collaboration.This article discussesed the pharmacist's role in this collaboration,as well as the administration of standard and novel therapies for MCL and the management of treatment related toxicities.

Indolent B-cell lymphomas constitute a slow growing cancer of the lymphatic system. These lymphomas mainly include fol-licular lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenstom macroglobulinemia, marginal zone lym-phoma, and low malignant mantle cell lymphoma. These lymphomas are sensitive to chemotherapy and/or immunochemotherapy, but they cannot be cured. Furthermore, patient age at diagnosis, patient age at time of first onset or subsequent relapses, and compli-cations often influence the chemotherapy curative effect. At present, recent progress has been achieved in our understanding of dys-regulated pathways and immunologic anti-tumor responses in indolent lymphoma. In particular, the breakthrough of non-cytotoxic drugs renderschemo-freetreatment a near-future reality. In this review, we highlight these promising approaches, such as the com-bination of anti-CD20 antibodies with immunomodulatory drugs, mAbs directed against other surface antigens, and programmed cell death 1 (PD-1) receptor inhibitor or B-cell receptor signaling pathway inhibitors. Future phase III studies will evaluate the efficacy of these drugs in the context of non-chemotherapy and further clarify treatment status.

To date, the treatment of peripheral T-cell lymphomas (PTCL) has lagged behind B-cell malignancies. Traditionally, para-digms for diffuse large B-cell lymphoma were applied to patients with PTCL, but the outcomes were poor. Recently, the FDA has ap-proved four drugs for patients with relapsed/refractory PTCL, and the Japanese government has approved of anti-CCR4 monoclonal an-tibody for patients with adult T-cell leukemia/lymphoma. Clinical studies are exploring the combination of these new agents into stan-dard CHOP-based regimens for patients with newly diagnosed PTCL. Recent studies have revealed that PTCL may be associated with epigenetic dysregulation and is thus sensitive to histone deacetylase inhibitors. These advances provide a new understanding of PTCL, whose therapeutic options will be presented in this review.

Bendamustine is a kind of nitrogen mustard derivatives consisting of a 2-chloroethylamine alkylating group and a benzimidazole ring.This special structure grants its anti-cancer mechanism different from other common alkylating agents with double function.Since approved,bendanustine has been widely used to treat henatologic malignancies and solid tumors such as breast cancer.In 2008,the FDA approved bendamustine injection for the treatment of chronic lymphocytic leukemia and indolent B cell non-Hodgkin's lymphoma.In recent years,scholars in China and abroad have carried out a series of clinical researches on single bendamustine and bendamsutine combinational chemotherapy,especially in hematologic malignancies,which obtained certain clinical efficacy.In this paper,the pharmacological actions,pharmacokinetics and clinical progress of bendamustine in lymphoma and leukemia are reviewed.

Hodgkin lymphoma (HL) originates from the lymphoid hematopoietic tissues and has a good treatment outcome with relatively high cure rate.Early stage HL is curable with abbreviated chemotherapy plus involved-filed radiotherapy or chemotherapy alone.However,patients with refractory or relapsed disease still lack effective treatment.In recent years,with the application of risk stratified treatment,novel drugs such as brentuximad vedotin,and PET-CT evaluation,significant progress has been made in prognosis and treatment of HL

Objective To evaluate protective efficacy of attenuated live hepatitis A vaccine.Methods We searched MEDLINE,EMBASE,CNKI.The randomization,concealment of allocation and blinding were included in the study. Results Meta analysis based on included studies showed that both strain of H2 and L-A-1 attenuated live hepatitis A vaccine had good protective efficacy,the protective efficacy is related to the titer of vaccine.The titer

Small cell lung cancer(SCLC) is an chemosensitive and radiosensitive malignant tumor which can appear hematogenous metastasis in early stage. The treatment of SCLC is based on chemotherapy and combined with radiotherapy and operation. In spite of the high response rate, the median time from drug-resistance to death of extensive SCLC is still disappointed. As to limited SCLC, there are still 75 % ~ 80 % patients relapse after inductive chemotherapy and radiotherapy. All in all, the second-line therapy is very important in SCLC patients.

Aggressive B-cell lymphoma is characterized by malignant behaviour and rapid progression.Patients are prone to drug resistance or relapse of disease.The 19th European Hematology Association (EHA)annual congress explored several aspects about aggressive B-cell lymphoma.PET-CT examination provided new tools for the indication of prognosis.The elevated dose of rituximab improved the outcome of elderly male patients.Novel drugs or methods including bortezomib,ABT-199,combined targeted therapy and CNS prophylaxis have shown encouraging results in various clinical trials which provide new hope for patients with aggressive B-cell lymphoma.